相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature
Cagatay Arslan et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer
Ebru Sari et al.
MEDICAL ONCOLOGY (2011)
Hormone Receptor and c-ERBB2 Status in Distant Metastatic and Locally Recurrent Breast Cancer
Pushpalatha K. A. Idirisinghe et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004
Monica Brown et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast
Kentaro Tamaki et al.
CANCER SCIENCE (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
Alastair M. Thompson et al.
BREAST CANCER RESEARCH (2010)
The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer
So Yeon Park et al.
AMERICAN JOURNAL OF SURGERY (2009)
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
M. Arnedos et al.
ANNALS OF ONCOLOGY (2009)
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
C. Liedtke et al.
ANNALS OF ONCOLOGY (2009)
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
C. Simmons et al.
ANNALS OF ONCOLOGY (2009)
Metastasis: from dissemination to organ-specific colonization
Don X. Nguyen et al.
NATURE REVIEWS CANCER (2009)
Immunohistochemically Determined Estrogen Receptor Phenotype Remains Stable in Recurrent and Metastatic Breast Cancer
Carmen Gomez-Fernandez et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases
Julie M. Wu et al.
CLINICAL CANCER RESEARCH (2008)
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management
Valentina Guarneri et al.
ONCOLOGIST (2008)
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
Alfredo Santinelli et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
HER-2/neu diagnostics in breast cancer
Walter P. Carney et al.
BREAST CANCER RESEARCH (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
HER2 gene status in primary breast cancers and matched distant metastases
Coya Tapia et al.
BREAST CANCER RESEARCH (2007)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer
HJ Kim et al.
CLINICAL CANCER RESEARCH (2006)
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
XJ Cui et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
G Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
J Zidan et al.
BRITISH JOURNAL OF CANCER (2005)
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
Y Gong et al.
CANCER (2005)
Impact of metastatic estrogen receptor and progesterone receptor status on survival
EE Lower et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Change of HER-2/neu status in a subset of distant metastases from breast carcinomas
P Regitnig et al.
JOURNAL OF PATHOLOGY (2004)
Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence
BL Schlechter et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome
C Iguchi et al.
JOURNAL OF SURGICAL ONCOLOGY (2003)
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
D Gancberg et al.
ANNALS OF ONCOLOGY (2002)
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process
A Vincent-Salomon et al.
CANCER (2002)
Progesterone receptor status of breast cancer metastases
M Brankovic-Magic et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2002)
Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression
WQ Zheng et al.
STEROIDS (2001)
Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer
R Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
